Loading clinical trials...

COMPLETEDNA

Evaluation of Effects of Dibifree® on Regulation of Blood Sugar and HbA1c in Patients With Type II Diabetes

NCT06224803•Global Preventive Medicine Biotech Co., Ltd.

Summary

At present, diabetic patients mainly use drugs to control blood sugar. However, drugs have side effects and the control effect varies among individuals. Even if diabetic patients can control their blood sugar well, long-term medication will still cause a series of complications, including retinopathy, nephropathy, diabetic foot, heart disease, etc. Vascular disease issues, etc. This study will focus on the changes in HbA1c and blood sugar in patients with confirmed diabetes after taking "Dibifree®" food supplement.

Eligibility

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age: 20 years old (inclusive) or above, gender is not restricted
•2. Diagnosed with type 2 diabetes
•3. HbA1c \> 6.5%
•4. Coagulation function and platelets are normal
•5. Participants voluntarily join this treatment course and sign the informed consent form
•6. Not taking other supplements containing blood sugar regulating properties for at least one month

Exclusion Criteria

•1. Women who are pregnant, lactating or planning to have children
•2. Have factors that significantly affect the absorption of oral drugs, such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.
•3. Uncontrolled hypertension (\>180/110 mmHG)
•4. People suffering from stroke, elderly dementia, Alzheimer's disease and other brain diseases
•5. During this study, the subject used other drugs or treatments that may interfere with this study in addition to blood sugar control medications.
•6. GOT\>4 times normal value; GPT\>4 times normal value
•7. Creatinine\>4 times the highest normal value
•8. Those who are determined by the project administrator to be unfit to participate in this clinical study

Locations (1)

Global Preventive Medicine Biotech Co., Ltd.

New Taipei City, NEW TAIPEI, Taiwan

Key Dates

Start Date

August 26, 2020

Primary Completion Date

July 21, 2021

Completion Date

January 18, 2022

Last Updated

July 16, 2025

Enrollment

ACTUAL participants

Conditions

Type II Diabetes

Interventions

Compound plant extracts

DIETARY_SUPPLEMENT

Indigestible dextrin

DIETARY_SUPPLEMENT

Engagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors

NCT07350694

Diabetes Type 2Type II Diabetes Mellitus

View study

RECRUITINGPHASE3

Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus

NCT05028140

Type II Diabetes

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 16, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of Effects of Dibifree® on Regulation of Blood Sugar and HbA1c in Patients With Type II Diabetes

Inclusion Criteria

Exclusion Criteria

Engagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors

Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus

Engagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors [EMPOWER-D]

Investigating the Syndrome Differentiation of Diabetic and Pre-diabetic Using Digitalized TCM Diagnostic Tools

A Clinical Trial to Evaluate the Food Effect of CKD-379

Initial Clinical Evaluation of an Endoscopic Therapy for Type 2 Diabetes